0001104659-21-065485.txt : 20210513 0001104659-21-065485.hdr.sgml : 20210513 20210513071535 ACCESSION NUMBER: 0001104659-21-065485 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210513 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210513 DATE AS OF CHANGE: 20210513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Liquidia Corp CENTRAL INDEX KEY: 0001819576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851710962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39724 FILM NUMBER: 21917172 BUSINESS ADDRESS: STREET 1: P.O. BOX 110085 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919.328.4400 MAIL ADDRESS: STREET 1: P.O. BOX 110085 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 8-K 1 tm2115707d2_8k.htm FORM 8-K
0001819576 false 0001819576 2021-05-13 2021-05-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 13, 2021

 

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)
     
Delaware 001-39724 85-1710962

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

     
419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (919) 328-4400

 

 
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock LQDA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

Item 2.02Results of Operations and Financial Condition.

 

On May 13, 2021, Liquidia Corporation, a Delaware corporation, issued a press release announcing its financial results for the three months ended March 31, 2021, and also provided a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.*

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

Exhibit
No.		   Exhibit
99.1   Press Release of Liquidia Corporation, dated May 13, 2021.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

May 13, 2021 Liquidia Corporation
   
   
  By: /s/ Michael Kaseta
    Name: Michael Kaseta
    Title: Chief Financial Officer

 

 

 

 EX-99.1 2 tm2115707d2_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Confidential Information (until released)

 

Liquidia Reports First Quarter 2021 Financial Results

and Provides Corporate Update

 

-      Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery

 

-      Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder

 

-      Improved financial position with private placement and access to new credit facility

 

-      Company to host webcast and conference call today at 8:30 a.m. ET

 

MORRISVILLE, N.C., May 13, 2021 - Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the quarter ended March 31, 2021. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the first quarter financial results and provide a corporate update.

 

Damian deGoa, Liquidia’s Chief Executive Officer, said: “This first quarter has been an important time of transition and re-structuring for the company as it strengthens its position and commitment to the products and patients that we support. We believe that our renewed focus and financial discipline are essential in order for the company to achieve its objectives in 2021 and beyond.”

 

Corporate Update

 

Enabled subcutaneous delivery of generic Treprostinil Injection, providing lower cost option to all patients on branded Remodulin. On March 26, 2021, the U.S. Food and Drug Administration (“FDA”) cleared the 510(k) application submitted by Liquidia PAH’s manufacturing partner, Chengdu Shifeng Medical Technologies LTD (“Chengdu”) for the RG 3ml Medication Cartridge which is indicated for use with the CADD-MS 3 pump. It is anticipated that Chengdu will start selling the RG 3ml Medication Cartridge in May, enabling the subcutaneous delivery of Treprostinil Injection for the first time. Until now, Treprostinil Injection could only be delivered by intravenous administration. The availability of the new cartridge will more than double the addressable market for Treprostinil Injection, which has been provided to patients with the same level of high-touch support and services as the branded product but at a lower cost since 2019.

 

Resubmitted NDA for LIQ861 (treprostinil) Inhalation Powder for the treatment of Pulmonary Arterial Hypertension (PAH). On May 7, 2021, the Company resubmitted its New Drug Application (“NDA”) for LIQ861 in response to the Complete Response Letter (“CRL”) received in November 2020. The resubmitted NDA was informed by discussion with FDA during a Type A meeting in January 2021 and included additional information and clarification on chemistry, manufacturing and controls pertaining to the drug product as well as data on device biocompatibility. No additional data from clinical trials or studies related to toxicology or clinical pharmacology was required. The Company anticipates that the FDA will classify the resubmitted NDA, if accepted, as a Class 2 Resubmission, which would result in a six-month review cycle from the date of resubmission.

 

Continued to defend right to advance innovation for PAH patients. In support of LIQ861, the Company is actively involved in Hatch-Waxman litigation brought by United Therapeutics Corporation (“United Therapeutics”), as well as pursuing inter partes review (“IPR”) of certain related patents at the U.S. Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”). In January 2021, the Company submitted a petition for IPR of U.S. Patent 10,716,793 (the “‘793 patent”), which was added in July 2020 to the Hatch-Waxman complaint filed by United Therapeutics. A decision by the PTAB whether to institute an IPR related to the ‘793 patent is expected in the third quarter of 2021 and, if instituted, a decision would be expected approximately 12 months from the date on which the IPR is instituted. A favorable decision invalidating this patent may also be considered by the court in the concurrent Hatch-Waxman litigation. Unless the Hatch-Waxman litigation is resolved earlier, the statutory 30-month regulatory stay as a result of the Hatch-Waxman litigation will expire in October 2022.

 

 

 

Confidential Information (until released)

 

Strengthened financial position by reducing annual net spending and increasing available cash resources. During the course of this year, the Company has taken several actions to improve the balance sheet as it progresses towards potential value-creating events in 2021 and 2022. Management implemented measures that reduced net annual spending in 2021 by more than 40% compared to 2020, which included, among other measures, reducing internal staff and consulting spending, refinancing equipment leases, and terminating development of LIQ865 to treat post-operative pain. The Company also refinanced its former credit facility with a new facility through Silicon Valley Bank that provides interest-only payments for 24 months, eliminating more than $10 million in required principal repayments over the next two years, while also providing access to an additional $10 million upon the achievement of key milestones paralleling FDA review of LIQ861. Lastly, the Company raised $21.7 million in April 2021 by entering a common stock purchase agreement with certain institutional investors led by Caligan Partners LP. At closing, David Johnson, a Partner and Co-Founder of Caligan Partners LP, was appointed to the board of directors of Liquidia Corporation as a Class II Director and a member of the Audit Committee.

 

First Quarter 2021 Financial Results

 

Cash totaled $53.6 million and $65.3 million as of March 31, 2021 and December 30, 2020, respectively. This cash total does not include proceeds from the private placement of common stock in April 2021.

 

Revenue of $3.1 million was recognized for the three months ended March 31, 2021 as compared to no revenue for the three months ended March 31, 2020. Revenue recognized during 2021 related to the promotion agreement with Sandoz Inc., after the acquisition of Liquidia PAH in November 2020.

 

Cost of revenue was $0.7 million for the three months ended March 30, 2021, compared to no cost of revenue for the three months ended March 31, 2020. Cost of revenue recognized during 2021 related to the promotion agreement as noted above.

 

Research and development expenses were $6.1 million for the three months ended March 31, 2021 compared with $10.8 million for the three months ended March 31, 2020, a decrease of $4.7 million or 44.1%. The decrease primarily related to lower expenses from our LIQ861 clinical program, which was substantially completed prior to filing the NDA in April 2020, lower expenses from our LIQ865 clinical program, and lower employee and consulting expenses.

 

General and administrative expenses were $5.3 million for the three months ended March 31, 2021, compared with $3.8 million for the three months ended March 31, 2020. The increase of $1.5 million, or 39.6%, was primarily due to $2.1 million higher legal and professional fees associated with corporate activities as well as our ongoing LIQ861-related litigation, offset by lower consulting and personnel expenses as a result of lower headcount year-over-year.

 

 

 

Confidential Information (until released)

 

Net loss for the quarter ended March 31, 2021 was $9.2 million, or $0.21 per basic and diluted share, compared to a net loss of $14.8 million, or $0.52 per basic and diluted share, for the quarter ended March 31, 2020.

 

Remodulin® (treprostinil) is a registered trademark of United Therapeutics Corporation.

 

CADD-MS® 3 is a registered trademark of Smiths Medical ASD, Inc.

 

About LIQ861

 

LIQ861 is an investigational inhaled dry powder formulation of treprostinil designed using Liquidia’s PRINT® technology with the goal of enhancing deep-lung delivery using a convenient, palm-sized dry powder inhaler for the treatment of pulmonary arterial hypertension (PAH). PRINT® technology enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for optimal deposition in the lung following oral inhalation. Liquidia believes LIQ861 can overcome the limitations of current inhaled therapies and has the potential to maximize the therapeutic benefits of treprostinil in treating PAH by safely delivering higher doses into the lungs. Liquidia has completed an open-label, multi-center phase 3 clinical study of LIQ861 in patients diagnosed with PAH known as INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil.

 

About Treprostinil Injection

 

Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration. Treprostinil Injection contains the same active ingredient, same strengths, same dosage form and same inactive ingredients as Remodulin® (treprostinil), and is offered to patients and physicians with the same level of service and support, but at a lower price than the branded drug. Liquidia PAH promotes the appropriate use of Treprostinil Injection for the treatment of PAH in the United States in partnership with its commercial partner, who holds the Abbreviated New Drug Application (ANDA) with the FDA.

 

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of PAH. Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as Treprostinil Injection. For more information, please visit www.liquidia.com.

 

 

 

Confidential Information (until released)

 

Cautionary Statements Regarding Forward-Looking Statements

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, including our response to the Complete Response Letter received in November 2020, the potential for eventual FDA approval of the NDA for LIQ861, the timeline or outcome related to our patent litigation pending in the U.S. District Court for the District of Delaware or our inter partes review with the PTAB, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, including the impact of the coronavirus (COVID-19) outbreak on our Company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact Information

 

Media & Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

 

 

 

Confidential Information (until released)

 

Liquidia Corporation

Select Balance Sheet Data

 

  

March 31,

2021

  

December 31,

2020

 
Cash  $53,637,155   $65,316,481 
Total assets  $88,451,874   $99,531,760 
Total liabilities  $25,542,695   $28,445,922 
Accumulated deficit  $(284,185,372)  $(275,002,219)
Total stockholders’ equity  $62,909,179   $71,085,838 

 

Liquidia Corporation

Consolidated Statements of Operations and Comprehensive Loss

 

   March 31, 
   2021   2020 
Revenue  $3,083,631   $— 
Costs and expenses:          
Cost of revenue   693,735    — 
Research and development   6,053,726    10,822,924 
General and administrative   5,337,253    3,823,197 
Total costs and expenses   12,084,714    14,646,121 
Loss from operations   (9,001,083)   (14,646,121)
Other income (expense):          
Interest income   20,766    109,590 
Interest expense   (202,836)   (254,948)
Total other income (expense), net   (182,070)   (145,358)
Net loss and comprehensive loss  $(9,183,153)  $(14,791,479)
Net loss per common share, basic and diluted  $(0.21)  $(0.52)
Weighted average common shares outstanding, basic and diluted   43,443,361    28,428,616 

 

 

 EX-101.SCH 3 lqda-20210513.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lqda-20210513_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lqda-20210513_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2115707d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001819576 2021-05-13 2021-05-13 iso4217:USD shares iso4217:USD shares 0001819576 false 8-K 2021-05-13 LIQUIDIA CORPORATION DE 001-39724 85-1710962 419 Davis Drive Suite 100 Morrisville NC 27560 919 328-4400 false false false false Common stock LQDA NASDAQ true true XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
May 13, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 13, 2021
Entity File Number 001-39724
Entity Registrant Name LIQUIDIA CORPORATION
Entity Central Index Key 0001819576
Entity Tax Identification Number 85-1710962
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 419 Davis Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Morrisville
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27560
City Area Code 919
Local Phone Number 328-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol LQDA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://liquidia.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2115707d2_8k.htm lqda-20210513.xsd lqda-20210513_lab.xml lqda-20210513_pre.xml tm2115707d2_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2115707d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2115707d2_8k.htm" ] }, "labelLink": { "local": [ "lqda-20210513_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "lqda-20210513_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "lqda-20210513.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lqda", "nsuri": "http://liquidia.com/20210513", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2115707d2_8k.htm", "contextRef": "From2021-05-13to2021-05-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://liquidia.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2115707d2_8k.htm", "contextRef": "From2021-05-13to2021-05-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-065485-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-065485-xbrl.zip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end